Roche Pharmaceutical Development and Sales Overview

ElecsysⓇ Amyloid Plasma Panel clinical results Addressing the unmet need of early detection of Alzheimer's disease pathology Roche AD patients Non-AD patients 1 1 Triage Patients undergoing initial evaluation for non-specific cognitive decline¹ Elecsys Amyloid Plasma Panel² pTau 181+APOE4 sensitivity>85% specificity > 65% FDA BDD 吧吧吧 EOE 吧吧吧 ਤਾਤ 2 Confirmation Patients referred for amyloid confirmatory testing³ Elecsys CSF AD assays4 pTau/Abeta 42 Therapy Patients identified for future therapies Anti-amyloid antibodies ° O sensitivity >90% specificity >90% 2 吧吧吧吧吧吧 EEE EEO 3 H Assumed prevalence of AD 30% in symptomatic patients; 2 Mean of clinical performance data from retrospective cohorts measured with Elecsys Amyloid Plasma Panel; 3 Alternative to PET scan; 4 FDA approval expected in Q4 2022 = 10 patients 41

View entire presentation